^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PDC*lung

i
Other names: PDC*lung, PDC*lung01, PDC-LUNG-101, LR19125, LR 19125, LR-19125
Associations
Company:
LG Chem, PDC line Pharma
Drug class:
MUC1 inhibitor, MAGE-A4 inhibitor, NY ESO 1 inhibitor, Survivin inhibitor, MAGE-A3 inhibitor, Melanoma cell surface antigen inhibitor, Multi-MAGE inhibitor
Related drugs:
Associations
2ms
PDC-LUNG-101: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (clinicaltrials.gov)
P1/2, N=73, Active, not recruiting, PDC*line Pharma SAS | Trial primary completion date: Dec 2025 --> Jul 2024
Trial primary completion date
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
Keytruda (pembrolizumab) • pemetrexed • PDC*lung
1year
PDC-LUNG-101: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (clinicaltrials.gov)
P1/2, N=73, Active, not recruiting, PDC*line Pharma SAS | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Dec 2025
Enrollment closed • Trial completion date • Trial primary completion date
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
Keytruda (pembrolizumab) • pemetrexed • PDC*lung
1year
PDC-LUNG-101: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (clinicaltrials.gov)
P1/2, N=64, Recruiting, PDC*line Pharma SAS | Trial completion date: Aug 2024 --> Sep 2025 | Trial primary completion date: Aug 2024 --> Sep 2025
Trial completion date • Trial primary completion date
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
Keytruda (pembrolizumab) • pemetrexed • PDC*lung
over1year
Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (clinicaltrials.gov)
P1/2, N=64, Recruiting, PDC*line Pharma SAS | Trial primary completion date: Aug 2022 --> Aug 2024
Trial primary completion date
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
Keytruda (pembrolizumab) • pemetrexed • PDC*lung
almost4years
Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (clinicaltrials.gov)
P1/2, N=64, Recruiting, PDC*line Pharma SAS | Trial completion date: Aug 2022 --> Aug 2024 | Trial primary completion date: Nov 2020 --> Aug 2022
Clinical • Trial completion date • Trial primary completion date
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
Keytruda (pembrolizumab) • pemetrexed • PDC*lung